Omnicell (OMCL) Competitors $30.42 +0.66 (+2.22%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$30.27 -0.15 (-0.49%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OMCL vs. MASI, AMN, WST, HSTM, MDRX, CRTX, IRTC, INSP, HNGE, and PRVAShould you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), Veradigm (MDRX), Cortexyme (CRTX), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), Hinge Health (HNGE), and Privia Health Group (PRVA). Omnicell vs. Its Competitors Masimo AMN Healthcare Services West Pharmaceutical Services HealthStream Veradigm Cortexyme iRhythm Technologies Inspire Medical Systems Hinge Health Privia Health Group Omnicell (NASDAQ:OMCL) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk. Do insiders & institutionals hold more shares of OMCL or MASI? 97.7% of Omnicell shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 2.5% of Omnicell shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, OMCL or MASI? Omnicell has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Masimo has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Is OMCL or MASI more profitable? Omnicell has a net margin of 2.01% compared to Masimo's net margin of -25.06%. Masimo's return on equity of 22.56% beat Omnicell's return on equity.Company Net Margins Return on Equity Return on Assets Omnicell2.01% 4.27% 2.44% Masimo -25.06%22.56%10.00% Which has better valuation & earnings, OMCL or MASI? Omnicell has higher earnings, but lower revenue than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmnicell$1.11B1.28$12.53M$0.5060.84Masimo$2.13B4.11-$304.90M-$9.17-17.59 Does the media refer more to OMCL or MASI? In the previous week, Omnicell had 8 more articles in the media than Masimo. MarketBeat recorded 19 mentions for Omnicell and 11 mentions for Masimo. Masimo's average media sentiment score of 0.86 beat Omnicell's score of 0.65 indicating that Masimo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 5 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Masimo 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend OMCL or MASI? Omnicell presently has a consensus target price of $45.33, suggesting a potential upside of 49.02%. Masimo has a consensus target price of $191.60, suggesting a potential upside of 18.81%. Given Omnicell's higher probable upside, equities analysts plainly believe Omnicell is more favorable than Masimo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Masimo 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryMasimo beats Omnicell on 9 of the 16 factors compared between the two stocks. Get Omnicell News Delivered to You Automatically Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMCL vs. The Competition Export to ExcelMetricOmnicellMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$2.06B$5.51B$9.35BDividend YieldN/AN/A4.74%4.16%P/E Ratio60.8436.9229.1724.41Price / Sales1.2846.02435.4290.24Price / Cash9.7254.1424.4827.20Price / Book1.139.368.495.77Net Income$12.53M-$63.67M$3.24B$264.99M7 Day Performance2.74%-4.20%0.63%-0.68%1 Month Performance2.91%4.55%7.95%7.08%1 Year Performance-23.95%16.36%30.47%23.80% Omnicell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMCLOmnicell3.6151 of 5 stars$30.42+2.2%$45.33+49.0%-22.4%$1.39B$1.11B60.843,670Earnings ReportMASIMasimo3.9003 of 5 stars$162.18-1.5%$191.60+18.1%+51.7%$8.79B$2.09B-17.695,600AMNAMN Healthcare Services4.3699 of 5 stars$19.71-0.5%$32.08+62.8%-72.7%$754.42M$2.98B-4.552,968Upcoming EarningsWSTWest Pharmaceutical Services4.589 of 5 stars$257.36-2.3%$320.71+24.6%-20.6%$18.49B$2.89B38.5310,600Positive NewsShort Interest ↑HSTMHealthStream4.4212 of 5 stars$26.79+0.1%$31.50+17.6%-10.9%$817.63M$291.65M42.521,093News CoverageEarnings ReportMDRXVeradigm2.2047 of 5 stars$4.68+0.6%$13.00+177.8%-49.7%$506.68M$1.53B0.008,000CRTXCortexymeN/A$1.85-0.5%N/A+140.0%$55.78MN/A-0.6255IRTCiRhythm Technologies1.8119 of 5 stars$137.11+2.2%$137.30+0.1%+123.3%$4.38B$618.59M-43.672,000Earnings ReportINSPInspire Medical Systems4.4596 of 5 stars$130.72+1.4%$208.55+59.5%-12.6%$3.86B$840.11M60.241,246Trending NewsEarnings ReportHNGEHinge HealthN/A$45.34-0.9%$49.36+8.9%N/A$3.54B$431.52M0.001,514PRVAPrivia Health Group3.6842 of 5 stars$19.70-0.1%$28.38+44.1%-2.6%$2.40B$1.74B164.181,140Upcoming Earnings Related Companies and Tools Related Companies Masimo Competitors AMN Healthcare Services Competitors West Pharmaceutical Services Competitors HealthStream Competitors Veradigm Competitors Cortexyme Competitors iRhythm Technologies Competitors Inspire Medical Systems Competitors Hinge Health Competitors Privia Health Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMCL) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
